The KLC1 Knockout Jurkat Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout cell population derived from the Jurkat human T lymphocyte line. This product provides a loss-of-function model generated through CRISPR/Cas9-mediated disruption of the KLC1 gene, encoding kinesin light chain 1. Because the population is polyclonal, it retains genetic heterogeneity that can mitigate clonal selection artifacts, offering a robust system for interrogating KLC1-dependent processes in a T cell context. The knockout model is supplied as a ready-to-use polyclonal pool, suitable for direct application in functional genomics, signal transduction studies, and drug discovery campaigns aimed at kinesin-mediated transport pathways.
The host cell background is the Jurkat E6-1 clone, an immortalized T lymphocyte line originally established from an acute T cell leukemia patient. Jurkat cells are CD3+ and CD28+, enabling analysis of T cell receptor (TCR)-proximal signaling events, and they harbor a mutated p53 gene, which facilitates their growth and survival independent of exogenous interleukin-2 (IL-2). This cell line is widely employed as a model for T cell activation, apoptosis, and cytokine signaling, making it particularly relevant for investigating how intracellular trafficking impacts immune cell function. The endogenous expression of relevant molecular machinery, including kinesin motor proteins and NF-??B pathway components, supports detailed mechanistic studies.
KLC1 functions as an essential adaptor that links cargo molecules to the kinesin-1 heavy chain (KIF5A, KIF5B, or KIF5C) for anterograde transport along microtubules. Through its tetratricopeptide repeat domains, KLC1 interacts with diverse cargos and scaffolding proteins, including TRAK1 (Milton), TRAK2, JIP1, huntingtin, RanBP2, 14-3-3 proteins, and the amyloid precursor protein (APP). This adaptor is critically involved in mitochondrial trafficking, Golgi vesicle transport, and synaptic vesicle dynamics. In the NF-??B signaling cascade, KLC1 contributes to the transmission of signals from the T cell receptor by mediating proximity between upstream kinases and the IKK complex; loss of KLC1 disrupts the phosphorylation and degradation of I??B??, thereby attenuating NF-??B (p65/p50) nuclear translocation. KLC1 activity is regulated by upstream kinases, such as GSK3??, JNK1, PKA, and CaMKII, as well as by neurotrophin signaling via NGF/TrkA, which collectively modulate cargo binding and motor activity.
In Jurkat T cells, efficient anterograde transport is essential for relaying activation signals from the plasma membrane to downstream effectors. KLC1 knockout in this background is predicted to impair mitochondrial redistribution and NF-??B signal transduction, both of which are central to T cell proliferation, survival, and effector function. This model thus offers a powerful tool to dissect the mechanistic interplay between kinesin-mediated transport and immune signaling. Furthermore, because KLC1 dysfunction is implicated in neurodegenerative disorders such as Charcot-Marie-Tooth disease, hereditary spastic paraplegia, and Alzheimer??s disease, studying this knockout in Jurkat cells provides a convenient, scalable platform to explore convergent mechanisms between neuronal and immune transport pathways.
Researchers can employ this knockout population to investigate a range of biological questions, including the role of KLC1 in mitochondrial dynamics under T cell activation conditions, the kinetic regulation of NF-??B signaling, and the trafficking requirements for surface receptor expression. Typical assays include Western blotting for KLC1 and I??B?? to confirm protein loss and pathway activation, flow cytometry for phospho-p65 to monitor NF-??B activity, live-cell imaging of mitochondrial movement, co-immunoprecipitation to detect KIF5?CKLC1 complex assembly, RT-qPCR for NF-??B target genes, and apoptosis or T cell activation assays. These cells are also amenable to small-molecule screening for transport modulators. For additional product details or technical support, please contact Ascent Research.
